ESR1 and breast carcinoma: A phase II trial sponsored by University Hospital, Essen investigated the efficacy and safety of Buparlisib with tamoxifen (an ER inhibitor) in ER/PR+, HER2- breast cancer patients with prior exposure to anti-hormonal therapy [128].